STAAR Surgical Company (STAA): Price and Financial Metrics
STAAR Surgical Company (STAA)
Today's Latest Price: $72.42 USD
Updated Dec 1 6:55pm
Add STAA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 143 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
STAA Stock Summary
- STAA's current price/earnings ratio is 372.48, which is higher than 97.8% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for STAA is currently 298.31, higher than 98.75% of US stocks with positive operating cash flow.
- With a price/sales ratio of 21.36, Staar Surgical Co has a higher such ratio than 91.86% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Staar Surgical Co are AOSL, GLUU, VICR, PCTY, and CALX.
- Visit STAA's SEC page to see the company's official filings. To visit the company's web site, go to www.staar.com.
STAA Stock Price Chart Interactive Chart >
STAA Price/Volume Stats
| Current price | $72.42 | 52-week high | $85.63 |
| Prev. close | $71.27 | 52-week low | $23.20 |
| Day low | $70.38 | Volume | 591,100 |
| Day high | $72.76 | Avg. volume | 559,274 |
| 50-day MA | $68.55 | Dividend yield | N/A |
| 200-day MA | $49.79 | Market Cap | 3.34B |
STAAR Surgical Company (STAA) Company Bio
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The company was founded in 1982 and is based in Monrovia, California.
STAA Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $72.42 | $0.99 | -99% |
Below please find a table outlining a discounted cash flow forecast for STAA, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Staar Surgical Co ranked in the 3th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Staar Surgical Co, consider:
- Staar Surgical Co's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -32.59. This coverage rate is greater than that of just 4.14% of stocks we're observing for the purpose of forecasting via discounted cash flows.
- As a business, Staar Surgical Co experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -99% |
| 1% | -99% |
| 2% | -99% |
| 3% | -99% |
| 4% | -99% |
| 5% | -99% |
CTLT, AGHC, ALC, AMRN, and ATRS can be thought of as valuation peers to STAA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...